Sarah Gooding

1.1k total citations
37 papers, 504 citations indexed

About

Sarah Gooding is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Sarah Gooding has authored 37 papers receiving a total of 504 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 20 papers in Molecular Biology and 16 papers in Oncology. Recurrent topics in Sarah Gooding's work include Multiple Myeloma Research and Treatments (25 papers), Protein Degradation and Inhibitors (16 papers) and Peptidase Inhibition and Analysis (9 papers). Sarah Gooding is often cited by papers focused on Multiple Myeloma Research and Treatments (25 papers), Protein Degradation and Inhibitors (16 papers) and Peptidase Inhibition and Analysis (9 papers). Sarah Gooding collaborates with scholars based in United Kingdom, United States and France. Sarah Gooding's co-authors include Carolyn Dorée, David J. Roberts, Susan J Brunskill, Sheila Fisher, Karthik Ramasamy, Onima Chowdhury, Claire M. Edwards, Anjan Thakurta, Timothy Hinks and Ajit Lalvani and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Sarah Gooding

33 papers receiving 491 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sarah Gooding United Kingdom 11 287 239 130 95 75 37 504
Foteini Theodorakakou Greece 12 218 0.8× 306 1.3× 177 1.4× 111 1.2× 128 1.7× 102 557
Zonghong Shao China 13 272 0.9× 146 0.6× 98 0.8× 69 0.7× 25 0.3× 80 540
Lena Oevermann Germany 12 236 0.8× 144 0.6× 198 1.5× 108 1.1× 43 0.6× 28 534
Maryam Behfar Iran 10 161 0.6× 141 0.6× 69 0.5× 72 0.8× 24 0.3× 68 415
Iuliana Vaxman Israel 13 147 0.5× 312 1.3× 150 1.2× 80 0.8× 18 0.2× 57 489
Henning D. Popp Germany 12 181 0.6× 141 0.6× 73 0.6× 84 0.9× 40 0.5× 32 438
Rama Al Hamed France 9 308 1.1× 236 1.0× 223 1.7× 56 0.6× 16 0.2× 11 487
Amine Belhabri France 14 272 0.9× 147 0.6× 95 0.7× 112 1.2× 26 0.3× 40 458
Mourad Tiab France 10 347 1.2× 270 1.1× 175 1.3× 41 0.4× 49 0.7× 42 407
S. Wittebol Netherlands 10 387 1.3× 198 0.8× 272 2.1× 114 1.2× 38 0.5× 16 581

Countries citing papers authored by Sarah Gooding

Since Specialization
Citations

This map shows the geographic impact of Sarah Gooding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Gooding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Gooding more than expected).

Fields of papers citing papers by Sarah Gooding

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Gooding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Gooding. The network helps show where Sarah Gooding may publish in the future.

Co-authorship network of co-authors of Sarah Gooding

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Gooding. A scholar is included among the top collaborators of Sarah Gooding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Gooding. Sarah Gooding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gooding, Sarah, et al.. (2024). Deletion of arrestin-3 does not reduce drug-seeking behavior in a longitudinal paradigm of oral morphine self-administration. Frontiers in Pharmacology. 15. 1438037–1438037. 2 indexed citations
2.
Teoh, Phaik Ju, et al.. (2024). Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond. Haematologica. 110(5). 1074–1091. 1 indexed citations
3.
Oekelen, Oliver Van, Michael Amatangelo, Manman Guo, et al.. (2024). Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma. Cell Reports Medicine. 5(6). 101584–101584. 7 indexed citations
4.
Agarwal, Gaurav, Lisa Ferguson, Jaimal Kothari, et al.. (2023). Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients. Blood. 142(Supplement 1). 644–644. 1 indexed citations
5.
Ramasamy, Karthik, Ross Sadler, Alison Turner, et al.. (2022). Immune response to COVID ‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response. British Journal of Haematology. 197(3). 293–301. 14 indexed citations
6.
Ansari‐Pour, Naser, Mehmet Samur, Erin Flynt, et al.. (2022). Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma. Blood. 141(6). 620–633. 22 indexed citations
7.
Welsh, Fenella K.S., John Connell, Matt Kelly, et al.. (2022). Precision medicine for liver tumours with quantitative MRI and whole genome sequencing (Precision1 trial): study protocol for observational cohort study. BMJ Open. 12(4). e057163–e057163. 2 indexed citations
8.
Gooding, Sarah, Naser Ansari‐Pour, Kübra Karagoz, et al.. (2022). Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma. Blood. 140(16). 1816–1821. 13 indexed citations
9.
Chen, Lucia & Sarah Gooding. (2022). Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma. Frontiers in Oncology. 12. 1038329–1038329. 7 indexed citations
10.
Oekelen, Oliver Van, Michael Amatangelo, Manman Guo, et al.. (2021). Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients. Blood. 138(Supplement 1). 730–730. 7 indexed citations
11.
12.
Gooding, Sarah, Naser Ansari‐Pour, Kübra Karagoz, et al.. (2021). Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients. Blood. 138(Supplement 1). 458–458.
13.
Amatangelo, Michael, Oliver Van Oekelen, Adeeb Rahman, et al.. (2019). Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients. Blood. 134(Supplement_1). 1775–1775. 9 indexed citations
14.
Olechnowicz, Sam W.Z., Megan Weivoda, Seint T. Lwin, et al.. (2019). Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment. Scientific Reports. 9(1). 14189–14189. 11 indexed citations
15.
Gooding, Sarah, Sam W.Z. Olechnowicz, Emma V. Morris, et al.. (2019). Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease. Nature Communications. 10(1). 4533–4533. 44 indexed citations
16.
Gooding, Sarah & Claire M. Edwards. (2016). New approaches to targeting the bone marrow microenvironment in multiple myeloma. Current Opinion in Pharmacology. 28. 43–49. 23 indexed citations
17.
King, Andrew J., Sarah Gooding, & Karthik Ramasamy. (2014). Managing multiple myeloma in the over 70s: A review. Maturitas. 80(2). 148–154. 5 indexed citations
18.
Eyre, Toby A., et al.. (2014). Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect. International Journal of Hematology. 99(6). 798–800. 9 indexed citations
19.
Millington, Kerry, Sarah Gooding, Timothy Hinks, David J. Reynolds, & Ajit Lalvani. (2010). Mycobacterium tuberculosis–Specific Cellular Immune Profiles Suggest Bacillary Persistence Decades after Spontaneous Cure in Untreated Tuberculosis. The Journal of Infectious Diseases. 202(11). 1685–1689. 43 indexed citations
20.
Gooding, Sarah, Timothy Hinks, Luca Richeldi, et al.. (2006). Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice. Journal of Infection. 54(3). e169–e174. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Foteini Theodorakakou Breakdown of academic impact, for papers by Zonghong Shao Breakdown of academic impact, for papers by Lena Oevermann Breakdown of academic impact, for papers by Maryam Behfar Breakdown of academic impact, for papers by Iuliana Vaxman Breakdown of academic impact, for papers by Henning D. Popp Breakdown of academic impact, for papers by Rama Al Hamed Breakdown of academic impact, for papers by Amine Belhabri Breakdown of academic impact, for papers by Mourad Tiab Breakdown of academic impact, for papers by S. Wittebol
Rankless by CCL
2026